$QGEN News

Qiagen N.V. (QGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Qiagen N.V. (QGEN) Presents at Deutsche Bank German Corporate Conference - Slideshow

Stifel Maintains Hold on Qiagen, Lowers Price Target to $36

Qiagen N.V. (QGEN) Price Target Decreased by 13.91% to 46.28

Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

QIAGEN's 2026 AGM To Feature 40% Dividend Increase To $0.35/Share, $200M Buyback And Co-Founder Colpan As Honorary Chairman

Qiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing - Slideshow

Qiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing Transcript

TD Cowen Maintains Hold on Qiagen, Lowers Price Target to $40

QIAGEN Plans To Advance QuantiFERON Latent TB Test With Automated Sample To Insight Workflow And Separate AI-Enabled Risk Stratification Tool For TB Progression

QIAGEN N.V. (NYSE:QGEN) Q1 Earnings Miss Estimates, Guidance Cut Sinks Stock

UPDATE: Qiagen FY2026 expected to be more than $2.43 vs $2.51 Est; Affirms FY2026 Sales Guidance of $2.111B-$2.132B vs $2.183B Est

Baird Upgrades Qiagen N.V. (QGEN)

JP Morgan Maintains Overweight on Qiagen, Lowers Price Target to $45

Citigroup Maintains Neutral on Qiagen, Lowers Price Target to $38

Barclays Maintains Equal-Weight on Qiagen, Lowers Price Target to $38

Baird Upgrades Qiagen to Outperform, Lowers Price Target to $43

Qiagen N.V. (QGEN) Q1 2026 Earnings Call Transcript

Qiagen N.V. 2026 Q1 - Results - Earnings Call Presentation

Barclays Downgrades Qiagen N.V. (QGEN)